Immunotherapy for psoriasis: From serendipity to selectivity

Lancet

Volumn 359, Issue 9303, 2002, Pages 279-280

  Griffiths, Christopher E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CD11 ANTIGEN; CD2 ANTIGEN; CD28 ANTIGEN; CD4 ANTIGEN; CD45 ANTIGEN; CYCLOSPORIN; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EFALUZIMAB; ETANERCEPT; GAMMA INTERFERON; HU 1124; HYBRID PROTEIN; IMMUNOGLOBULIN G1; INFLIXIMAB; INTERFERON ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 8; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIGEN PRESENTING CELL; AVOIDANCE BEHAVIOR; CELL INTERACTION; CELL PROLIFERATION; CLINICAL TRIAL; COMPLEX FORMATION; CREAM; CROHN DISEASE; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SPECIFICITY; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOTHERAPY; KERATINOCYTE; LYMPHOCYTE FUNCTION; MORBIDITY; NATURAL KILLER CELL; NOTE; OINTMENT; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN TARGETING; PSORIASIS; PSORIATIC ARTHRITIS; PSYCHOSOCIAL DISORDER; QUALITY OF LIFE; SKIN INFLAMMATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; TH1 CELL; TREATMENT OUTCOME;

EID: 0037176566     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)07536-0     Document Type: Note

References (16)

1. Cyclosporin A for psoriasis
2. Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial
3. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens?
4. Successful in vivo blockage of CD25 (high affinity interleukin-2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis
5. The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibody
6. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes
7. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA41g) reverses the cellular pathology of psoriatic plaques, including the activation of keratinoyctes, dendritic cells, and endothelial cells
8. Treatment with anti-tumor necrosis factor-a (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
9. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: A randomised trial
10. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
11. T cells involved in psoriasis vulgaris belong to the Th1 subset
12. Expression of interleukin-12 is increased in psoriatic skin
13. Interleukin 10 treatment of psoriasis: Clinical results of a phase 2 trial
14. Quality of life in patients with psoriasis: The contribution of clinical variables and psoriasis-specific stress
15. The impact of psoriasis on quality of life: Results of a 1998 National Psoriasis Foundation patient membership survey
16. Patients with psoriasis and their compliance with medication